Haemophilia drug costing $3.5m per dose has been approved
Pharmafile
NOVEMBER 23, 2022
CSL Behring’s haemophilia B gene therapy has recently been approved by US regulators, however the treatment has an enormous price tag. The treatment also seemed to free 94% of patients from expensive and time-consuming infusions of Factor IX, which is the current standard of care for the often fatal condition. Costing $3.5m
Let's personalize your content